These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37492039)

  • 1. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.
    Mahrous M; Omar Jebriel A; Allehebi A; Shafik A; El Karak F; Venturini F; Alhusaini H; Meergans M; Ali Nahit Sendur M; Ouda M; Al-Nassar M; Kilickap S; Al Turki S; Al-Fayea T; Abdel Kader Y
    Cureus; 2023 Jul; 15(7):e41992. PubMed ID: 37492039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
    J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
    Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
    Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 
Skipping Mutation].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
    Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
    JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of
    Subramanian J; Tawfik O
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
    Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
    Front Oncol; 2022; 12():786124. PubMed ID: 35280795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with
    Digumarthy SR; Mendoza DP; Zhang EW; Lennerz JK; Heist RS
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861060
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracranial response to capmatinib after progression on crizotinib in a patient with
    Jóri B; Bundschuh O; Falk M; Heukamp LC; Kluge A; Tiemann M; Willborn KC; Woitzik J; Griesinger F
    Transl Lung Cancer Res; 2024 Jul; 13(7):1749-1755. PubMed ID: 39118880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
    Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
    BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
    Tian J; Lin Z; Chen Y; Fu Y; Ding Z
    Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment.
    Huang S; Li L; Yan N; Zhang H; Guo Q; Guo S; Geng D; Liu X; Li X
    Front Oncol; 2024; 14():1331387. PubMed ID: 38706592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
    Fraser M; Seetharamu N; Diamond M; Lee CS
    Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
    Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
    Front Oncol; 2021; 11():649766. PubMed ID: 34249687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian Consensus Recommendations on the Management of
    Cheema PK; Banerji SO; Blais N; Chu QS; Desmeules P; Juergens RA; Leighl NB; Sheffield BS; Wheatley-Price PF; Melosky BL
    Curr Oncol; 2021 Nov; 28(6):4552-4576. PubMed ID: 34898564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.